Neurocrine Biosciences
NBIX
#1615
Rank
A$18.59 B
Marketcap
A$185.23
Share price
-1.19%
Change (1 day)
18.29%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): A$7.28

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$6.82. an increase over its 2024 EPS that were of A$4.78.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025A$6.5937.87%
2024A$4.7833.07%
2023A$3.5957.76%
2022A$2.2869.47%
2021A$1.34-78.21%
2020A$6.17990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.310.62%
2016A-$2.2957.28%
2015A-$1.4625.61%
2014A-$1.1618.84%
2013A-$0.98-1085.71%
2012A$0.09905

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.92-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$3.38-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$32.58 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.23-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.87-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$2.42-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$42.31-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.49-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK